You are currently viewing our site as a guest, which gives you limited access to our site features. By signing up for a free membership, you will receive our Investment Opportunity newsletters and have access to additional features for finding and comparing managed funds and shares. Registration is fast and simple, so please:
Business Description: Antisense Therapeutics Limited (ANP) is a biopharmaceutical drug discovery and development company. The company has four products including ATL1102 injection for Multiple Scherosis, ATL1103 injection for growth & sight disorders, ATL1101 injection for prostate cancer, and ATL1102 inhaled for asthma.
Strategy Analysis: Antisense Therapeutics is a biopharmaceutical drug discovery and development company. Its mission is to create, develop and commercialize antisense pharmaceuticals for large unmet markets.
A fundamental element of ANP´s strategy is access to leading antisense technology via a strategic partnership with Isis Pharmaceuticals Inc. Isis currently has one antisense drug on the market and 18 products in development (either alone or in partnership with other pharmaceutical companies). It has partnerships with major pharmaceutical companies, including Genzyme, Eli Lilly & Co, Bristol-Myers Squibb, and Johnson & Johnson. The collaboration with Isis provides ANP with access to Isis´ antisense intellectual property, drug discovery technology, development expertise and drug manufacturing capabilities.
ANP has two drugs in development and two drugs in pre-clinical research. ATL/TV1102 (injection) has completed a Phase IIa trial as a potential treatment of multiple sclerosis. ATL1103 is a second generation antisense drug designed to lower blood IGF-I levels and is entering pre-clinical development as a potential treatment for acromegaly and vision disorders. ATL/TV1102 (inhaled) is at the pre-clinical research stage as a potential treatment for asthma. ATL1101 is a second-generation antisense drug at the pre-clinical research stage being investigated as a potential treatment for prostate cancer. ATL/TV1102 has been licensed to Teva Pharmaceutical Industries Ltd.
An educational booklet to help you learn the language of residential property financing with an introduction on how the tax system can help improve your cashflow.
The Age 26/05/2012 | I WAS reading some old Marcus Today newsletters. From 2003. Let me take you back and allow you to exercise the power of hindsight:
The Age 25/05/2012 | RADIO People are six times more likely to go to an advertiser's website if they have heard the ad on radio, according to research by Colmar Brunton, released by Commercial Radio Australia. The research showed that radio advertising has an immediate effect on people's digital activity, with more than three-quarters of those exposed to advertising visiting a website or Facebook page or searching for the brand online within 24 hours. Commercial Radio Australia chief executive Joan Warner said the ...
Already a member? 
